Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy
Issued Date
2022-12-01
Resource Type
ISSN
17449979
eISSN
17449987
Scopus ID
2-s2.0-85124623154
Pubmed ID
35067000
Journal Title
Therapeutic Apheresis and Dialysis
Volume
26
Issue
6
Start Page
1098
End Page
1105
Rights Holder(s)
SCOPUS
Bibliographic Citation
Therapeutic Apheresis and Dialysis Vol.26 No.6 (2022) , 1098-1105
Suggested Citation
Thongprayoon C., Cheungpasitporn W., Radhakrishnan Y., Zabala Genovez J.L., Petnak T., Shawwa K., Qureshi F., Mao M.A., Kashani K.B. Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy. Therapeutic Apheresis and Dialysis Vol.26 No.6 (2022) , 1098-1105. 1105. doi:10.1111/1744-9987.13804 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85348
Title
Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy
Author's Affiliation
Other Contributor(s)
Abstract
Introduction: We aimed to assess the association between serum potassium and mortality in patients receiving continuous renal replacement therapy (CRRT). Methods: We studied 1279 acute kidney injury patients receiving CRRT in a tertiary referral hospital in the United States. We used logistic regression to assess the association of serum potassium before CRRT and mean serum potassium during CRRT with 90-day mortality after CRRT initiation, using serum potassium 4.0–4.4 mmol/L as reference group. Results: Before CRRT, there was a U-shaped association between serum potassium and 90-day mortality. There was a significant increase in mortality when serum potassium before CRRT was ≤3.4 and ≥4.5 mmol/L. During CRRT, progressively increased mortality was noted when mean serum potassium was ≥4.5 mmol/L. The odds ratio of 90-day mortality was significantly higher when mean serum potassium was ≥4.5 mmol/L. Conclusion: Hypokalemia and hyperkalemia before CRRT and hyperkalemia during CRRT predicts 90-day mortality.